When blood glucose returns to the normal range, the activation efficiency of this signaling pathway decreases with the decline in blood glucose, and insulin secretion is correspondingly reduced (Henquin, 2000), thereby reducing the clinical risk of hypoglycemia at the molecular mechanism level. This evidence concerns the gene INS and Hypoglycemia.